Alzheimer Disease: Mouse Models Pave the Way for Therapeutic Opportunities
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Research into the molecular mechanisms of Alzheimer disease (AD) continues to clarify important issues in aberrant protein processing while seeking to identify therapeutic targets. Mutations of genes on chromosomes 1, 14 (presenilins 1 and 2), and 21 (the amyloid-beta [Abeta] amyloid precursor protein [APP]) cause the familial forms of AD that often begin before age 65. An allelic polymorphism on chromosome 19 (apolipoprotein E ) affects the age of onset of the more common forms of sporadic AD. Multiple studies in transgenic mice provide strong evidence to support the view that Abeta amyloid formation is an early and critical pathogenic event: mice expressing pathogenic human APP mutations develop Abeta deposits; coexpression of mutant presenilin genes accelerates the rate of Abeta deposition; and apolipoprotein E plays a role in this process. Thus, the 3 established genetic causes or risk factors for AD affect Abeta deposition. The fact that elevation of the Abeta42/Abeta40 ratio (differing only in 2 amino acids in length) is also linked to amyloid deposition in the APP mice and is temporally linked to cognitive impairment suggests that Abeta42 may be a principal inducing factor of AD. The exact sequence of events is still unknown, but the transgenic models generated so far have shown their usefulness in clarifying this complex part of the pathology. The continuing progress in elucidation of the molecular pathogenesis of AD suggests a range of rational pharmacological interventions for this disorder. The most promising strategy involves the development of approaches to retard, halt, or prevent Abeta-mediated disease progression, and these can now be tested in transgenic animals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · cited 1×
“Surprisingly, FAD-linked PS1/PS2 variants influence processing at the g-secretase site and may cause AD by increasing the extracellular concentration of highly amyloidogenic Ab42 species, thus fostering Ab deposition in the brain.(11) The age of onset of AD in families harboring PS1 mutations is young, ranging from 30…”
BackgroundDeficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
Skeletal and CNS Defects in Presenilin-1-Deficient Mice
Shen, J., Bronson, R. T., Chen, D. F., Xia, W., Selkoe, D. J., & Tonegawa, S. (1997) · Cell · doi:10.1016/s0092-8674(00)80244-5 · Cited by 959
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Du Yan, S., Fu, J., Soto, C., Chen, X., Zhu, H., Al-Mohanna, F., Collison, K., Zhu, A., Stern, E., Saido, T., et al. (1997) · Nature · doi:10.1038/39522 · Cited by 379 · cited 1×
“Recent evidence suggests that Ab binds an intracellular polypeptide known as endoplasmic-reticulum– associated binding protein (ERAB), which is overexpressed in neurons affected in AD.(17) The ERAB sequence indicates that it might be an enzyme such as a hydroxysteroid dehydrogenase or an acetoacetyl-CoA reductase.”
BackgroundPedersen, W. A., Kloczewiak, M. A., & Blusztajn, J. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.8068 · Cited by 134
Cited by
Alzheimer disease and cerebrovascular pathology: an update
Jellinger, K. A. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200068 · Cited by 680
“…evidence from transgenic models now indicates that mutation in the A domain of neuronal APP may predispose to a vascular pathology, whereas mutations outside the A domain lead to more neuronal pathology (Emilien et al., 2000; Grabowski et al., 2000; Holtzman et al., 2000; Masliah et al., 2001).”
BackgroundRegulation of APP cleavage by α‐, β‐ and γ‐secretases
Nunan, J., & Small, D. H. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02076-7 · Cited by 512
Oxidative injury in diseases of the central nervous system: focus on alzheimer’s disease
Praticò, D., & Delanty, N. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00547-7 · Cited by 378
Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357
Protein misfolding and disease; protein refolding and therapy
Soto, C. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02486-3 · Cited by 336
Behl, C., & Moosmann, B. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00883-3 · Cited by 302
Dhanasekaran, M., Holcomb, L. A., Hitt, A. R., Tharakan, B., Porter, J. W., Young, K. A., & Manyam, B. V. (2009) · Phytotherapy Research · doi:10.1002/ptr.2405 · Cited by 175
“The combination of these two mutations results in an increased production of amyloid β peptide with initial deposition of plaques detectable as early as 3–4 months of age (Emilien et al., 2000; Holcomb et al., 1998; Holcomb et al., 1999; McGowan et al., 1999; Gordon et al., 2002).”
BackgroundBacopa monniera extract reduces amyloid levels in PSAPP mice
Holcomb, L. A., Dhanasekaran, M., Hitt, A. R., Young, K. A., Riggs, M., & Manyam, B. V. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9303 · Cited by 156
Harrison, S. M., Harper, A. J., Hawkins, J., Duddy, G., Grau, E., Pugh, P. L., Winter, P. H., Shilliam, C. S., Hughes, Z. A., Dawson, L. A., et al. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00227-6 · Cited by 152
White, F., Nicoll, J. A. R., Roses, A. D., & Horsburgh, K. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0401 · Cited by 128
Metadata
- Authors
- Emilien, G., Maloteaux, J.-M., Beyreuther, K., & Masters, C. L.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2000-02-01
- Volume
- 57
- Issue
- 2
- Pages
- 176
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2091660037
- Cited by
- 55
- References
- 9
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.